BioStem Technologies Inc.(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced ...

BioStem Technologies®, a leading regenerative medicine company focused on developing and commercializing placental-derived biologics, today announced that the United States Patent and Trademark Office ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. With no fresh headline event driving attention to BioStem Technologies (BSEM), recent ...

Ungrodt brings nearly three decades of financial leadership to the role, having spent her career as a senior partner at Ernst & Young advising life sciences companies on initial and secondary public ...

BioStem Technologies (OTCMKTS:BSEM) said its first quarter of 2026 marked a major shift in its business model following a ...

BioStem Technologies Inc (BSEM) shifts focus to hospital markets, aiming for growth through acquisitions and NASDAQ uplisting.

POMPANO BEACH, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech ...

EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has ...

POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of ...

BioStem Technologies Inc. company and executive profile by Barron's. View the latest BSEM company infomation and executive bios.

Company reports record preliminary fourth quarter net revenue of $102.9 Million, contributing to a total of $301.8 Million in revenue for 2024 Achieves preliminary GAAP net income of $15.5 million, or ...